Study Reveals Heart Pump Device Ineffective in Diminishing Heart Attack Size
A heart pump device, usually employed 30 minutes before an artery-clearing procedure called percutaneous coronary intervention (PCI) in patients suffering from a specific type of heart attack, has failed to decrease the size of the heart attack. This was revealed in a study aimed at understanding the effectiveness of the heart pump device in treating patients with anterior ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock.
Furthermore, the study found an increased risk of serious bleeding and vascular complications associated with the use of the heart pump device when compared to PCI alone.
Despite optimistic preclinical data indicating that left ventricular (LV) unloading might decrease heart attack size, medical experts advise against using the heart pump device in patients with anterior STEMI without cardiogenic shock.
Learning from the Findings
Although the study did not yield positive results, it provided valuable insights that could guide future research and improve patient care. The study also prompted discussions about the higher occurrence of major bleeding and vascular complications associated with the heart pump device. Experts suggest that these complications are a trade-off for reducing the heart attack size.
The study's findings will not deter the use of the heart pump device in patients with cardiogenic shock, but its use in anterior STEMI patients is now questionable.
The Quest for a Heart Attack Size Reducing Therapy
The medical field has been on a long journey to discover a therapy that could reduce the size of a myocardial infarction and subsequently improve patient outcomes, including survival. However, previous attempts using pharmaceutical and device therapies have not been successful, and none of the approaches have become a part of the standard care.
With the heart pump device, the risk-to-benefit ratio is clear. There is a sixfold higher incidence of major bleeding or vascular complications. However, these risks are not offset by any clinical benefits or efficacy in reducing the heart attack size.
Limitations of the Study
It's important to note that the study excluded patients with cardiogenic shock. Hence, the results do not apply to shock patients who undergo PCI and require the device, potentially more for hemodynamic support rather than for reducing the heart attack size.
Understanding the Heart Pump Device
The heart pump device is a temporary ventricular support device used during high-risk PCI procedures in elective or urgent patients who are hemodynamically stable. It is also approved for treating ongoing cardiogenic shock following acute myocardial infarction or open-heart surgery or in the setting of cardiomyopathy or myocarditis due to isolated LV failure.
Future Research Directions
While the heart pump device did not show significant impact on reducing the size of heart attacks, experts are hopeful that modifying the patient selection or approach could potentially yield different results. For instance, focusing on patients with low blood pressure, but who do not meet the definition of cardiogenic shock, could be one potential area of exploration.
This study, although negative, has provided valuable insights and opened up new avenues for further investigations, highlighting the importance of continuous research in the field of medicine.